BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Piramal Enterprises Ltd. has uniquely positioned itself in the pharma business to not only leverage from its niche business model but also capitalise on the upcoming organic and inorganic opportunities that augur well for future growth.
The company organised a virtual conference to discuss the pharma business in great depth and we have encapsulated the key highlights from that discussion below.
The company is the 13th largest player in the global contract development and manufacturing organization market with an approximate target market size of $55-70 billion.
The company generates most of its revenues from commercial manufacturing and development services by servicing clients across the spectrum (big pharma, generics, emerging biopharma, etc).
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.